0000899243-20-015623.txt : 20200608 0000899243-20-015623.hdr.sgml : 20200608 20200608161707 ACCESSION NUMBER: 0000899243-20-015623 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200604 FILED AS OF DATE: 20200608 DATE AS OF CHANGE: 20200608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cadavid Diego CENTRAL INDEX KEY: 0001778713 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 20949323 MAIL ADDRESS: STREET 1: C/O FULCRUM THERAPEUTICS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-04 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001778713 Cadavid Diego C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 0 1 0 0 SVP Clinical Development Common Stock 2020-06-04 4 M 0 226 4.83 A 67011 D Common Stock 2020-06-04 4 S 0 226 20.0498 D 66785 D Common Stock 2020-06-05 4 M 0 451 4.83 A 67236 D Common Stock 2020-06-05 4 S 0 451 20.1791 D 66785 D Stock Option (right to buy) 4.83 2020-06-04 4 M 0 226 0.00 D 2028-07-10 Common Stock 226 14588 D Stock Option (right to buy) 4.83 2020-06-05 4 M 0 451 0.00 D 2028-07-10 Common Stock 451 14137 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. /s/ Peter Thomson, as attorney-in-fact for Diego Cadavid 2020-06-08